MCID: ATR057
MIFTS: 55

Atrioventricular Block

Categories: Cardiovascular diseases

Aliases & Classifications for Atrioventricular Block

MalaCards integrated aliases for Atrioventricular Block:

Name: Atrioventricular Block 12 29 54 6 43 15 71
Av Block 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:0050820
ICD9CM 34 426.10
MeSH 43 D054537
NCIt 49 C26703
SNOMED-CT 67 58547007
ICD10 32 I44.3 I44.30
UMLS 71 C0004245

Summaries for Atrioventricular Block

Disease Ontology : 12 A heart conduction disease that is characterized by the impairment of the conduction between the atria and ventricles of the heart.

MalaCards based summary : Atrioventricular Block, also known as av block, is related to first-degree atrioventricular block and second-degree atrioventricular block. An important gene associated with Atrioventricular Block is SCN5A (Sodium Voltage-Gated Channel Alpha Subunit 5), and among its related pathways/superpathways are Cardiac conduction and cGMP-PKG signaling pathway. The drugs Nebivolol and Telmisartan have been mentioned in the context of this disorder. Affiliated tissues include heart, atrioventricular node and testes, and related phenotypes are cardiovascular system and growth/size/body region

Wikipedia : 74 Atrioventricular block (AV block) is a type of heart block that occurs when the electrical signal... more...

Related Diseases for Atrioventricular Block

Diseases related to Atrioventricular Block via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 514, show less)
# Related Disease Score Top Affiliating Genes
1 first-degree atrioventricular block 34.9 SCN5A MYH7 LMNA CA5B
2 second-degree atrioventricular block 34.4 TRIM21 SSB SCN5A HCN4 CA5B
3 third-degree atrioventricular block 34.1 TTN TRIM21 SSB SCN5A NPPB HCN4
4 progressive familial heart block, type ia 33.4 SCN5A SCN1A MYH7
5 progressive familial heart block 32.5 TRPM4 SCN5A NKX2-5 KCNQ1
6 syncope 32.1 TTN SCN5A KCNQ1 KCNH2
7 progressive familial heart block, type ib 31.6 TRPM4 SCN5A
8 sick sinus syndrome 31.6 TTN SCN5A LMNA HCN4
9 left bundle branch hemiblock 31.5 SCN5A PIK3C2A NPPB LMNA
10 inferior myocardial infarction 31.4 PIK3C2A NPPB CA5B
11 mitral valve insufficiency 31.3 TBX5 NPPB MYH7
12 cardiac conduction defect 31.2 SCN5A MYH7 LMNA KCNQ1 KCNH2
13 heart septal defect 31.2 TBX5 NKX2-5 MYH7 GATA4 CA5B
14 right bundle branch block 31.2 TRPM4 SCN5A NPPB KCNH2 HCN4 CA5B
15 ventricular septal defect 31.1 TBX5 NPPB NKX2-5 MYH7 GATA4
16 ventricular fibrillation, paroxysmal familial, 1 31.1 SCN5A NKX2-5 KCNQ1 KCNH2 KCNE2 KCNE1
17 dextro-looped transposition of the great arteries 31.0 TBX5 NPPB NKX2-5 GATA4
18 atrial standstill 1 31.0 TTN SCN5A NPPB MYH7 LMNA GATA4
19 familial long qt syndrome 31.0 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
20 hypokalemia 31.0 PIK3C2A KCNQ1 KCNH2
21 hypertrophic cardiomyopathy 30.9 TTN SCN5A MYH7 LMNA HCN4 CRYAB
22 atrial heart septal defect 30.8 TTN TBX5 SCN5A NPPB NKX2-5 MYH7
23 tricuspid atresia 30.8 TBX5 NKX2-5 GATA4
24 sinoatrial node disease 30.7 TBX5 SCN5A NKX2-5 KCNQ1 KCNH2 KCNE2
25 heart valve disease 30.7 NPPB NKX2-5 MYH7 GATA4
26 rare cardiomyopathy 30.7 TTN MYH7 LMNA
27 cardiac arrhythmia 30.7 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
28 coronary artery anomaly 30.6 SCN5A PIK3C2A NPPB NKX2-5 KCNH2 GATA4
29 muscular dystrophy 30.5 TTN PIK3C2A NKX2-5 MYH7 LMNA CRYAB
30 restrictive cardiomyopathy 30.5 TTN TRPM4 NPPB MYH7 LMNA CRYAB
31 peripartum cardiomyopathy 30.4 TTN SCN5A MYH7
32 congestive heart failure 30.4 TTN SCN5A PIK3C2A NPPB MYH7 KCNQ1
33 patent ductus arteriosus 1 30.4 TBX5 NPPB NKX2-5 GATA4
34 hypoplastic left heart syndrome 30.4 TBX5 NPPB NKX2-5 MYH7 GATA4
35 long qt syndrome 30.4 TTN TRPM4 SCN5A MYH7 LMNA KCNQ1
36 long qt syndrome 3 30.4 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
37 endocardial fibroelastosis 30.3 TRIM21 SSB NPPB MYH7 CA5B
38 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 30.3 SCN5A MYH7 KCNQ1 KCNH2
39 cardiac arrest 30.3 TTN TRPM4 SCN5A PIK3C2A NPPB MYH7
40 double outlet right ventricle 30.3 TBX5 NKX2-5 GATA4
41 aortic valve disease 1 30.3 TBX5 NKX2-5 HCN4 GATA4
42 atrioventricular septal defect 30.3 TBX5 NKX2-5 GATA4
43 aortic valve disease 2 30.3 TTN TBX5 NPPB NKX2-5 MYH7 GATA4
44 respiratory failure 30.3 TTN PIK3C2A NPPB MYH7 GATA4
45 wolff-parkinson-white syndrome 30.2 TBX5 SCN5A NPPB NKX2-5 MYH7 KCNQ1
46 miyoshi muscular dystrophy 30.2 TTN PIK3C2A MYH7
47 atrial fibrillation 30.1 TTN TBX5 SCN5A NPPB MYH7 LMNA
48 jervell and lange-nielsen syndrome 1 30.1 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
49 neuromuscular disease 30.1 TTN SCN5A MYH7 LMNA CRYAB
50 long qt syndrome 2 30.1 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
51 tetralogy of fallot 30.1 TBX5 SCN5A NPPB NKX2-5 MYH7 KCNH2
52 ebstein anomaly 29.7 TBX5 SCN5A NPPB NKX2-5 MYH7 HCN4
53 dilated cardiomyopathy 29.6 TTN TBX5 SCN5A NPPB NKX2-5 MYH7
54 left ventricular noncompaction 29.6 TTN TBX5 SCN5A NKX2-5 MYH7 LMNA
55 arrhythmogenic right ventricular cardiomyopathy 29.4 TTN TRPM4 SCN5A NPPB MYH7 LMNA
56 heart disease 29.2 TTN TBX5 SCN5A PIK3C2A NPPB NKX2-5
57 brugada syndrome 28.9 TTN TRPM4 TBX5 SCN5A SCN1A NKX2-5
58 familial atrial fibrillation 28.6 TTN TRPM4 TBX5 SCN5A NKX2-5 MYH7
59 mobitz type ii atrioventricular block 12.7
60 heart block, congenital 12.2
61 myocarditis 10.8
62 acute myocardial infarction 10.7
63 sarcoidosis 1 10.6
64 myocardial infarction 10.6
65 cardiac sarcoidosis 10.6
66 endocarditis 10.6
67 familial sick sinus syndrome 10.5 SCN5A HCN4
68 familial short qt syndrome 10.5 KCNQ1 KCNH2
69 familial isolated arrhythmogenic ventricular dysplasia, left dominant form 10.5 TTN LMNA
70 heart, malformation of 10.5 TBX5 NKX2-5
71 familial isolated arrhythmogenic ventricular dysplasia, biventricular form 10.5 TTN LMNA
72 familial isolated arrhythmogenic ventricular dysplasia, right dominant form 10.5 TTN LMNA
73 cardiogenic shock 10.5
74 laminopathy 10.5 SCN5A LMNA
75 brugada syndrome 4 10.5 SCN5A KCNQ1 KCNH2
76 lupus erythematosus 10.5
77 acute myocarditis 10.5
78 rigid spine muscular dystrophy 1 10.4 TTN MYH7 LMNA
79 toxic myocarditis 10.4 PIK3C2A NPPB
80 cardiomyopathy, dilated, 1b 10.4 TTN SCN5A MYH7 LMNA
81 eisenmenger syndrome 10.4 NKX2-5 GATA4
82 double discordia 10.4
83 long qt syndrome 11 10.4 KCNQ1 KCNE2 KCNE1
84 congenital fiber-type disproportion 10.4 TTN MYH7 LMNA
85 myopathy 10.4
86 hypogonadotropic hypogonadism 5 with or without anosmia 10.4 TBX5 NKX2-5 GATA4
87 lyme disease 10.4
88 total anomalous pulmonary venous return 1 10.4 TBX5 NKX2-5 GATA4
89 long qt syndrome 10 10.4 SCN5A KCNQ1 KCNH2 KCNE2
90 ischemia 10.4
91 hemopericardium 10.4
92 pericardial effusion 10.4
93 long qt syndrome 9 10.4 SCN5A KCNQ1 KCNE2 KCNE1
94 extrinsic cardiomyopathy 10.4 TTN PIK3C2A NPPB
95 autoimmune disease 10.4
96 infective endocarditis 10.4
97 rheumatic fever 10.4
98 familial isolated dilated cardiomyopathy 10.3 TTN SCN5A MYH7 CRYAB
99 pulmonary valve stenosis 10.3 TBX5 SCN5A NKX2-5 GATA4
100 kearns-sayre syndrome 10.3
101 tricuspid valve insufficiency 10.3
102 coronary stenosis 10.3
103 pulmonary valve disease 10.3 TBX5 NPPB NKX2-5 GATA4
104 leopard syndrome 10.3 TBX5 MYH7 KCNQ1 KCNH2
105 myofibrillar myopathy 10.3 TTN MYH7 LMNA CRYAB
106 hyperlipoproteinemia, type iii 10.3
107 pericarditis 10.3
108 aortic valve insufficiency 10.3
109 connective tissue disease 10.3
110 b-cell lymphoma 10.3
111 constrictive pericarditis 10.3 TTN NPPB
112 arteries, anomalies of 10.3
113 systemic lupus erythematosus 10.3
114 atrioventricular dissociation 10.3
115 lymphoma 10.3
116 hypothyroidism 10.3
117 hyperthyroidism 10.3
118 muscle tissue disease 10.3 TTN PIK3C2A MYH7 LMNA
119 long qt syndrome 6 10.3 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
120 long qt syndrome 13 10.3 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
121 long qt syndrome 12 10.3 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
122 long qt syndrome 5 10.3 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
123 andersen cardiodysrhythmic periodic paralysis 10.3 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
124 timothy syndrome 10.3 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
125 myasthenic syndrome, congenital, 5 10.3 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
126 rheumatic fever-related antigen 10.3
127 aneurysm 10.3
128 neonatal lupus erythematosus 10.3
129 pericardium disease 10.3 TRIM21 PIK3C2A NPPB
130 cardiomyopathy, dilated, 1e 10.3 TTN SCN5A SCN1A MYH7 LMNA
131 holt-oram syndrome 10.2 TBX5 NKX2-5 MYH7 LMNA GATA4
132 hydrops fetalis, nonimmune 10.2
133 angina pectoris 10.2
134 visual epilepsy 10.2
135 chronic kidney disease 10.2
136 pulmonary embolism 10.2
137 congenitally corrected transposition of the great arteries 10.2
138 pure autonomic failure 10.2
139 fainting 10.2
140 seizure disorder 10.2
141 mononeuritis of upper limb and mononeuritis multiplex 10.2 TRIM21 SSB
142 graves' disease 10.2
143 mononeuritis multiplex 10.2 TRIM21 SSB
144 parotid disease 10.2 TRIM21 SSB
145 malignant hyperthermia 10.2 SCN5A PIK3C2A MYH7
146 tricuspid valve disease 10.2 TBX5 NPPB NKX2-5 MYH7 CA5B
147 rheumatoid arthritis 10.2
148 scleroderma, familial progressive 10.2
149 chronic progressive external ophthalmoplegia 10.2
150 intermediate coronary syndrome 10.2
151 broken heart syndrome 10.2
152 atrial septal defect 5 10.2 TBX5 NKX2-5
153 patent foramen ovale 10.1 TRPM4 TBX5 NPPB NKX2-5 GATA4
154 ocular motor apraxia 10.1
155 graves disease 1 10.1
156 orthostatic intolerance 10.1
157 resting heart rate, variation in 10.1
158 diffuse large b-cell lymphoma 10.1
159 pulmonary edema 10.1
160 echinococcosis 10.1
161 pneumothorax 10.1
162 benign mesothelioma 10.1
163 temporal lobe epilepsy 10.1
164 situs inversus 10.1
165 arthritis 10.1
166 rheumatic myocarditis 10.1
167 dextrocardia 10.1
168 47,xyy 10.1
169 short qt syndrome 10.1 TRPM4 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
170 cyanide poisoning 10.1
171 brugada syndrome 1 10.1 SCN5A KCNH2
172 muscular dystrophy, duchenne type 10.1
173 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.1
174 acute promyelocytic leukemia 10.1
175 leukemia, acute lymphoblastic 10.1
176 spastic paraplegia, intellectual disability, nystagmus, and obesity 10.1
177 rheumatic heart disease 10.1
178 sleep apnea 10.1
179 colitis 10.1
180 lymphocytic leukemia 10.1
181 allergic hypersensitivity disease 10.1
182 chagas disease 10.1
183 endomyocardial fibrosis 10.1
184 uveitis 10.1
185 diarrhea 10.1
186 rheumatic disease 10.1
187 thrombocytopenia 10.1
188 mitral valve stenosis 10.1
189 vascular disease 10.1
190 epilepsy 10.1
191 lipid metabolism disorder 10.1
192 aortitis 10.1
193 vasculitis 10.1
194 chickenpox 10.1
195 amyloidosis 10.1
196 systolic heart failure 10.1
197 giant cell myocarditis 10.1
198 infectious myocarditis 10.1
199 parotitis 10.0 TRIM21 SSB
200 sarcoma 10.0
201 dengue hemorrhagic fever 10.0
202 spindle cell sarcoma 10.0
203 schizoaffective disorder 10.0
204 congenital myasthenic syndrome 10.0 TTN SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
205 cardiomyopathy, familial restrictive, 1 10.0
206 pheochromocytoma 10.0
207 pneumothorax, primary spontaneous 10.0
208 trigeminal neuralgia 10.0
209 neuropathy, hereditary sensory and autonomic, type iii 10.0
210 hemochromatosis, type 1 10.0
211 myxedema 10.0
212 heterotaxy, visceral, 5, autosomal 10.0
213 thymoma, familial 10.0
214 mucopolysaccharidosis, type ii 10.0
215 stroke, ischemic 10.0
216 branchiootic syndrome 1 10.0
217 anorexia nervosa 10.0
218 coronary heart disease 1 10.0
219 chorea, childhood-onset, with psychomotor retardation 10.0
220 hydrops, lactic acidosis, and sideroblastic anemia 10.0
221 pulmonary hypertension 10.0
222 metabolic acidosis 10.0
223 adrenal gland pheochromocytoma 10.0
224 ptosis 10.0
225 tonsillitis 10.0
226 diphtheria 10.0
227 hypertensive heart disease 10.0
228 emery-dreifuss muscular dystrophy 10.0
229 mucopolysaccharidosis iii 10.0
230 choreatic disease 10.0
231 typhoid fever 10.0
232 toxic shock syndrome 10.0
233 alcohol use disorder 10.0
234 lymphadenitis 10.0
235 hyperuricemia 10.0
236 transient cerebral ischemia 10.0
237 arteriosclerosis 10.0
238 hemangioma 10.0
239 acute pancreatitis 10.0
240 gastric dilatation 10.0
241 thymoma 10.0
242 lactic acidosis 10.0
243 liver cirrhosis 10.0
244 arteriolosclerosis 10.0
245 kidney disease 10.0
246 subvalvular aortic stenosis 10.0
247 anterolateral myocardial infarction 10.0
248 posterior myocardial infarction 10.0
249 muscular atrophy 10.0
250 end stage renal failure 10.0
251 appendicitis 10.0
252 ulcerative colitis 10.0
253 mitochondrial encephalomyopathy 10.0
254 cholangitis 10.0
255 meningitis 10.0
256 hypoglycemia 10.0
257 heterotaxy 10.0
258 myotonic dystrophy 10.0
259 sickle cell disease 10.0
260 bronchogenic cyst 10.0
261 cardiac hydatid cysts with intracavitary expansion 10.0
262 lymphosarcoma 10.0
263 single ventricular heart 10.0
264 dysautonomia 10.0
265 posttransplant acute limbic encephalitis 10.0
266 digitalis poisoning 10.0
267 premature aging 10.0
268 levocardia 10.0
269 long qt syndrome 1 9.9 SCN5A NKX2-5 MYH7 KCNQ1 KCNH2 KCNE2
270 atrial septal defect 7 with or without atrioventricular conduction defects 9.9
271 diaphragmatic hernia, congenital 9.9
272 huntington disease 9.9
273 sarcoma, synovial 9.9
274 left ventricular noncompaction 1 9.9
275 dengue virus 9.9
276 charcot-marie-tooth disease 9.9
277 abducens nerve disease 9.9
278 tooth disease 9.9
279 choledocholithiasis 9.9
280 coronary artery vasospasm 9.9
281 pulmonary sarcoidosis 9.9
282 glycogen storage disease 9.9
283 intermittent claudication 9.9
284 cocaine abuse 9.9
285 heart aneurysm 9.9
286 dextrocardia with situs inversus 9.9
287 headache 9.9
288 virus-associated trichodysplasia spinulosa 9.9
289 colchicine poisoning 9.9
290 pseudohypoparathyroidism, type ia 9.8
291 alcohol dependence 9.8
292 spondyloarthropathy 1 9.8
293 annular erythema 9.8
294 apnea, obstructive sleep 9.8
295 atherosclerosis susceptibility 9.8
296 gastroesophageal reflux 9.8
297 bladder cancer 9.8
298 breast cancer 9.8
299 hepatocellular carcinoma 9.8
300 cardiomyopathy, dilated, 1a 9.8
301 creatine phosphokinase, elevated serum 9.8
302 multiple sclerosis 9.8
303 hernia, hiatus 9.8
304 hypercholesterolemia, familial, 1 9.8
305 hypertelorism 9.8
306 hypertelorism, teebi type 9.8
307 meckel diverticulum 9.8
308 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 1 9.8
309 myositis 9.8
310 neurofibromatosis, type i 9.8
311 neurofibromatosis, type iv, of riccardi 9.8
312 hutchinson-gilford progeria syndrome 9.8
313 pulmonary hypertension, primary, 1 9.8
314 schizophrenia 9.8
315 small cell cancer of the lung 9.8
316 supravalvular aortic stenosis 9.8
317 down syndrome 9.8
318 cardiomyopathy, familial hypertrophic, 1 9.8
319 widow's peak 9.8
320 takayasu arteritis 9.8
321 argininosuccinic aciduria 9.8
322 right atrial isomerism 9.8
323 central hypoventilation syndrome, congenital 9.8
324 c syndrome 9.8
325 lung cancer 9.8
326 miller-dieker lissencephaly syndrome 9.8
327 mandibuloacral dysplasia with type a lipodystrophy 9.8
328 myasthenia gravis 9.8
329 myeloma, multiple 9.8
330 myopathy, congenital 9.8
331 netherton syndrome 9.8
332 sjogren syndrome 9.8
333 adrenomyodystrophy 9.8
334 muscular dystrophy, becker type 9.8
335 fabry disease 9.8
336 sickle cell anemia 9.8
337 ascaris lumbricoides infection 9.8
338 nasopharyngeal carcinoma 9.8
339 anxiety 9.8
340 sick sinus syndrome 1 9.8
341 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 2 9.8
342 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 3 9.8
343 syndactyly, mesoaxial synostotic, with phalangeal reduction 9.8
344 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 4 9.8
345 kawasaki disease 9.8
346 major affective disorder 8 9.8
347 major affective disorder 9 9.8
348 pseudopseudohypoparathyroidism 9.8
349 lung cancer susceptibility 3 9.8
350 microvascular complications of diabetes 3 9.8
351 microvascular complications of diabetes 4 9.8
352 microvascular complications of diabetes 6 9.8
353 microvascular complications of diabetes 7 9.8
354 muscular dystrophy, congenital, lmna-related 9.8
355 cyanosis, transient neonatal 9.8
356 aspergillosis 9.8
357 membranous nephropathy 9.8
358 leukemia, acute lymphoblastic 3 9.8
359 striatal degeneration, autosomal dominant 2 9.8
360 helix syndrome 9.8
361 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.8
362 peripheral vascular disease 9.8
363 deficiency anemia 9.8
364 bacterial sepsis 9.8
365 invasive aspergillosis 9.8
366 hemophagocytic lymphohistiocytosis 9.8
367 erythema multiforme 9.8
368 lissencephaly 9.8
369 exanthem 9.8
370 multinodular goiter 9.8
371 inflammatory bowel disease 9.8
372 extrapulmonary tuberculosis 9.8
373 paraganglioma 9.8
374 fibroma 9.8
375 dental abscess 9.8
376 intrahepatic cholestasis of pregnancy 9.8
377 cryptococcal meningitis 9.8
378 dermatomyositis 9.8
379 open-angle glaucoma 9.8
380 renal hypertension 9.8
381 brucellosis 9.8
382 anhidrosis 9.8
383 arteriovenous malformation 9.8
384 cardiac tamponade 9.8
385 listeriosis 9.8
386 inflammatory spondylopathy 9.8
387 aseptic meningitis 9.8
388 goiter 9.8
389 dengue disease 9.8
390 bell's palsy 9.8
391 leiomyoma 9.8
392 guillain-barre syndrome 9.8
393 megaesophagus 9.8
394 skin sarcoidosis 9.8
395 tuberous sclerosis 9.8
396 hyperparathyroidism 9.8
397 cholestasis 9.8
398 biliary atresia 9.8
399 opisthorchiasis 9.8
400 amenorrhea 9.8
401 ochronosis 9.8
402 adult-onset still's disease 9.8
403 hypoglycemic coma 9.8
404 duodenal ulcer 9.8
405 cholecystitis 9.8
406 cerebral palsy 9.8
407 enthesopathy 9.8
408 constipation 9.8
409 focal epilepsy 9.8
410 spondylosis 9.8
411 relapsing polychondritis 9.8
412 myoma 9.8
413 glomerulonephritis 9.8
414 adenocarcinoma 9.8
415 ascaridiasis 9.8
416 aspiration pneumonitis 9.8
417 rhabdomyosarcoma 9.8
418 thymic carcinoma 9.8
419 bipolar disorder 9.8
420 purpura 9.8
421 mammary paget's disease 9.8
422 cellulitis 9.8
423 systemic mastocytosis 9.8
424 mixed connective tissue disease 9.8
425 mastocytosis 9.8
426 aortic aneurysm 9.8
427 external ear disease 9.8
428 arthropathy 9.8
429 placental insufficiency 9.8
430 lung squamous cell carcinoma 9.8
431 liver disease 9.8
432 syphilis 9.8
433 systemic scleroderma 9.8
434 pseudohypoparathyroidism 9.8
435 pustulosis of palm and sole 9.8
436 uremia 9.8
437 angiokeratoma 9.8
438 cavernous hemangioma 9.8
439 pancreatitis 9.8
440 paget's disease of bone 9.8
441 peripheral nervous system disease 9.8
442 discrete subaortic stenosis 9.8
443 posteroinferior myocardial infarction 9.8
444 anteroseptal myocardial infarction 9.8
445 acquired immunodeficiency syndrome 9.8
446 heart lymphoma 9.8
447 adenoma 9.8
448 spondylitis 9.8
449 cerebrovascular disease 9.8
450 spinal stenosis 9.8
451 mediastinal malignant lymphoma 9.8
452 mitochondrial metabolism disease 9.8
453 thyroiditis 9.8
454 axonal neuropathy 9.8
455 mediastinitis 9.8
456 retinal degeneration 9.8
457 influenza 9.8
458 polyhydramnios 9.8
459 reticulosarcoma 9.8
460 herpes simplex 9.8
461 oral cavity cancer 9.8
462 tongue cancer 9.8
463 neuropathy 9.8
464 crohn's disease 9.8
465 psoriasis 9.8
466 achalasia 9.8
467 lymphangitis 9.8
468 diabetes mellitus 9.8
469 hypopituitarism 9.8
470 sarcocystosis 9.8
471 trichinosis 9.8
472 congenital syphilis 9.8
473 hydrocele 9.8
474 limb-girdle muscular dystrophy 9.8
475 lmna-related dilated cardiomyopathy 9.8
476 mitochondrial disorders 9.8
477 48,xyyy 9.8
478 aneurysm of sinus of valsalva 9.8
479 baroreflex failure 9.8
480 chromosomal triplication 9.8
481 complete atrioventricular canal 9.8
482 growth hormone deficiency 9.8
483 macrophage activation syndrome 9.8
484 mercury poisoning 9.8
485 mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes 9.8
486 polymyositis 9.8
487 retroperitoneal fibrosis 9.8
488 splenomegaly 9.8
489 raynaud phenomenon 9.8
490 anoxia 9.8
491 autonomic dysfunction 9.8
492 cerebral hypoxia 9.8
493 cytomegalovirus infection 9.8
494 dysphagia 9.8
495 encephalopathy 9.8
496 head injury 9.8
497 hypertonia 9.8
498 hypoxia 9.8
499 mucopolysaccharidoses 9.8
500 myotonia 9.8
501 spinocerebellar degeneration 9.8
502 interatrial communication 9.8
503 progressive muscular dystrophy 9.8
504 univentricular heart 9.8
505 immune hydrops fetalis 9.8
506 serotonin syndrome 9.8
507 atrial septal aneurysm 9.8
508 congenital gerbode defect 9.8
509 skeletal muscle disease 9.8
510 metabolic myopathy 9.8
511 catecholaminergic polymorphic ventricular tachycardia 9.8 TRPM4 SCN5A MYH7 LMNA KCNQ1 KCNH2
512 muscular disease 9.7 TTN TRIM21 SCN5A PIK3C2A MYH7 LMNA
513 intrinsic cardiomyopathy 9.6 TTN SCN5A NPPB NKX2-5 MYH7 LMNA
514 heart conduction disease 9.6 TRIM21 SCN5A NPPB KCNQ1 KCNH2 KCNE2

Comorbidity relations with Atrioventricular Block via Phenotypic Disease Network (PDN): (showing 13, show less)


Acute Cystitis Aortic Valve Disease 1
Deficiency Anemia Familial Atrial Fibrillation
First-Degree Atrioventricular Block Heart Disease
Hypertension, Essential Intermediate Coronary Syndrome
Mitral Valve Disease Right Bundle Branch Block
Sinoatrial Node Disease Third-Degree Atrioventricular Block
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Atrioventricular Block:



Diseases related to Atrioventricular Block

Symptoms & Phenotypes for Atrioventricular Block

MGI Mouse Phenotypes related to Atrioventricular Block:

45 (showing 6, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.18 GATA4 HCN4 KCNH2 KCNQ1 LMNA MYH7
2 growth/size/body region MP:0005378 10.1 CA5B GATA4 KCNE2 KCNH2 KCNQ1 LMNA
3 homeostasis/metabolism MP:0005376 10.1 CA5B CRYAB GATA4 KCNE2 KCNH2 KCNQ1
4 mortality/aging MP:0010768 10 CA5B GATA4 HCN4 KCNH2 LMNA MYH7
5 muscle MP:0005369 9.7 CRYAB GATA4 HCN4 KCNH2 KCNQ1 LMNA
6 normal MP:0002873 9.32 GATA4 HCN4 KCNQ1 LMNA MYH7 NKX2-5

Drugs & Therapeutics for Atrioventricular Block

Drugs for Atrioventricular Block (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 150, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
2
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
3
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
4
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
5
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
6
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
7
Enalaprilat Approved Phase 4 76420-72-9 6917719
8
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
9
tannic acid Approved Phase 4 1401-55-4
10
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
11
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
12
Bisoprolol Approved Phase 4 66722-44-9 2405
13
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
14
Ticagrelor Approved Phase 4 274693-27-5 9871419
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
16
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
17
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
18
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
19
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
20
Ramipril Approved Phase 4 87333-19-5 5362129
21
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
22
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
23
Remifentanil Approved Phase 4 132875-61-7 60815
24
Pseudoephedrine Approved Phase 4 90-82-4 7028
25
Ephedrine Approved Phase 4 299-42-3 9294
26
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
27
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
28
Procainamide Approved Phase 4 51-06-9 4913
29
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
30
Choline Approved, Nutraceutical Phase 4 62-49-7 305
31 Adrenergic beta-Agonists Phase 4
32 Angiotensin II Type 1 Receptor Blockers Phase 4
33 Giapreza Phase 4
34 Sodium Chloride Symporter Inhibitors Phase 4
35 Angiotensinogen Phase 4
36 Hormone Antagonists Phase 4
37 Anti-Inflammatory Agents Phase 4
38 Hormones Phase 4
39 Analgesics Phase 4
40 Anesthetics Phase 4
41 Calcium, Dietary Phase 4
42 calcium channel blockers Phase 4
43 Adrenergic Agonists Phase 4
44 Hypnotics and Sedatives Phase 4
45 Adrenergic alpha-2 Receptor Agonists Phase 4
46 Anesthetics, General Phase 4
47 Analgesics, Non-Narcotic Phase 4
48 Anesthetics, Intravenous Phase 4
49 Nootropic Agents Phase 4
50 Cytidine Diphosphate Choline Phase 4
51 Adrenergic alpha-Antagonists Phase 4
52 Antioxidants Phase 4
53 Natriuretic Peptide, Brain Phase 4
54 Protective Agents Phase 4
55 Platelet Aggregation Inhibitors Phase 4
56 Anti-Inflammatory Agents, Non-Steroidal Phase 4
57 Cyclooxygenase Inhibitors Phase 4
58 Antipyretics Phase 4
59 Antirheumatic Agents Phase 4
60 Purinergic P2Y Receptor Antagonists Phase 4
61 Anesthetics, Local Phase 4
62 Adjuvants, Anesthesia Phase 4
63 Natriuretic Agents Phase 4
64 Mineralocorticoids Phase 4
65 diuretics Phase 4
66 Mineralocorticoid Receptor Antagonists Phase 4
67 Sodium Potassium Chloride Symporter Inhibitors Phase 4
68 Antihypertensive Agents Phase 4
69 Neurotransmitter Agents Phase 4
70 Adrenergic Agents Phase 4
71 Adrenergic beta-Antagonists Phase 4
72 Adrenergic Antagonists Phase 4
73 HIV Protease Inhibitors Phase 4
74
protease inhibitors Phase 4
75 Angiotensin-Converting Enzyme Inhibitors Phase 4
76 Adrenergic beta-1 Receptor Antagonists Phase 4
77 Autonomic Agents Phase 4
78 Sympatholytics Phase 4
79 Angiotensin Receptor Antagonists Phase 4
80 Central Nervous System Depressants Phase 4
81 Narcotics Phase 4
82 Analgesics, Opioid Phase 4
83 Anti-Arrhythmia Agents Phase 4
84 Vasodilator Agents Phase 4
85 Cytochrome P-450 CYP3A Inhibitors Phase 4
86 Cytochrome P-450 Enzyme Inhibitors Phase 4
87 Potassium Channel Blockers Phase 4
88 Sodium Channel Blockers Phase 4
89 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
90 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
91 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
92 Diuretics, Potassium Sparing Phase 4
93
Diltiazem Approved, Investigational Phase 2, Phase 3 42399-41-7 39186
94
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
95
Acetylcholine Approved, Investigational Phase 1, Phase 2 51-84-3 187
96
leucovorin Approved Phase 2 58-05-9 6006 143
97
Hydroxyurea Approved Phase 2 127-07-1 3657
98
Verapamil Approved Phase 2 52-53-9 2520
99
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
100
Lactitol Investigational Phase 2 585-86-4, 585-88-6 493591
101 Immunologic Factors Phase 2
102 Fingolimod Hydrochloride Phase 2
103 Plasminogen Phase 2
104 Tissue Plasminogen Activator Phase 2
105 Immunosuppressive Agents Phase 2
106 Trace Elements Phase 2
107 Vitamins Phase 2
108 Micronutrients Phase 2
109 Vitamin B Complex Phase 2
110 Vitamin B9 Phase 2
111 Nutrients Phase 2
112 Hematinics Phase 2
113 Folate Phase 2
114 Acetylcholine Release Inhibitors Phase 1, Phase 2
115 Neuromuscular Agents Phase 1, Phase 2
116 Botulinum Toxins Phase 1, Phase 2
117 abobotulinumtoxinA Phase 1, Phase 2
118 insulin Phase 1, Phase 2
119 Insulin, Globin Zinc Phase 1, Phase 2
120 Cholinergic Agents Phase 1, Phase 2
121 Botulinum Toxins, Type A Phase 1, Phase 2
122 Anti-Retroviral Agents Phase 2
123 Pharmaceutical Solutions Phase 2
124
Adenosine Approved, Investigational Phase 1 58-61-7 60961
125
Calcium carbonate Approved, Investigational Phase 1 471-34-1
126
Clonidine Approved Phase 1 4205-90-7 2803
127
Methadone Approved Phase 1 76-99-3 4095
128
Guaifenesin Approved, Investigational, Vet_approved Phase 1 93-14-1 3516
129
Lofexidine Approved, Investigational Phase 1 31036-80-3 30668
130
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 1 52485-79-7 40400 644073
131 Liver Extracts Phase 1
132 Respiratory System Agents Phase 1
133 Antitussive Agents Phase 1
134 Chlorpheniramine, phenylpropanolamine drug combination Phase 1
135 Narcotic Antagonists Phase 1
136
Latanoprost Approved, Investigational 130209-82-4 5282380 5311221
137
Etodolac Approved, Investigational, Vet_approved 41340-25-4 3308
138
Propranolol Approved, Investigational 525-66-6 4946